This study systematically summarizes the immunogenicity and clinical translational potential of various universal influenza vaccine candidates, providing critical platform comparisons and analyses of protection correlates for the field of influenza vaccine design, offering direct guidance for optimizing antigen selection and evaluation strategies.
Literature Overview
This article, 'Advances in the Development of a Universal Influenza Vaccine,' published in the journal Antibodies, systematically explores current progress in universal influenza vaccine (UIV) development, covering multiple antigen targets and vaccine platforms, and evaluates their potential to overcome challenges such as antigenic drift and immune imprinting. The article reviews the immunogenicity of conserved antigens including the HA stalk, NP, and M2e, and further analyzes the advantages and limitations of different platforms in inducing cross-reactive antibodies and T-cell immunity. The study emphasizes that although existing candidates have demonstrated safety and immunogenicity in early clinical trials, long-term protective efficacy and consistency across populations remain key bottlenecks.Background Knowledge
Influenza virus causes approximately 1 billion infections and hundreds of thousands of deaths annually, posing a continuous threat to global public health. Current seasonal influenza vaccines (SIVs) rely on annual predictions of circulating strains and corresponding updates to vaccine components, but are often limited by antigenic drift and shift, leading to mismatched strains and fluctuating vaccine effectiveness. Additionally, SIVs primarily induce antibodies targeting the highly variable head region of hemagglutinin (HA), which fails to provide broad protection. Therefore, targeting highly conserved regions of the virus—such as the HA stalk, nucleoprotein (NP), M2e, or neuraminidase (NA)—has become a core strategy for UIVs. However, existing challenges include immune imprinting limiting responses to conserved epitopes, a lack of correlates of broad protection, and viral genetic plasticity that may lead to escape mutations. This study focuses on integrating the latest evidence from multi-platform UIV candidates to systematically evaluate their ability to overcome these bottlenecks, particularly in terms of optimizing immune responses through structural design, vector selection, and antigen presentation strategies.
Research Methods and Experiments
The authors conducted a systematic review of various UIV candidates at preclinical and clinical stages, encompassing recombinant protein, nanoparticle, viral vector, mRNA, whole inactivated virus, and intranasal live-attenuated vaccine platforms. By analyzing immunogenicity data from Phase I/II clinical trials, the study assessed each platform’s ability to induce cross-reactive antibodies and T-cell responses. For example, nanoparticle vaccines such as FluMos-v1 and H1ssF, which multivalently display HA antigens, have successfully induced broad neutralizing antibodies against the HA stalk—even overcoming pre-existing immunodominance of HA head-specific immunity in individuals. mRNA platforms such as H1ssF-3928 combine rapid development advantages with in vivo antigen expression, enabling more flexible iterative optimization. Additionally, T-cell-targeted vaccines like OVX836 and ChAdOx1NP+M1, which express internal proteins such as NP and M1, activate CD4+ and CD8+ T cells, offering heterosubtypic protection.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a critical roadmap for the clinical translation of universal influenza vaccines. From a drug development perspective, a multi-platform parallel strategy can accelerate the screening of optimal candidates, with mRNA and nanoparticle platforms offering particularly rapid response potential. In terms of clinical monitoring, standardized correlates of broad protection—such as stalk-IgG, NAI titers, and T-cell functional assays—need to be established to support regulatory approval. Furthermore, incorporating UIVs into childhood immunization programs may reduce interference from immune imprinting, establish a broader immune baseline, and have profound implications for building population-level immunity.
Conclusion
The development of a universal influenza vaccine represents a critical step toward shifting from passive response to proactive defense. Although challenges such as immune imprinting, antigenic variation, and the lack of correlates of protection remain, multiple platforms have already demonstrated the potential to induce broad immune responses. In particular, strategies targeting the HA stalk and internal proteins, combined with novel delivery systems, may enable single-dose, long-term protection. Future research should focus on validating clinical efficacy through large-scale Phase III trials and optimizing antigen design to counter viral evolution. From the laboratory to the clinic, UIVs have the potential not only to reduce the burden of annual vaccine updates but also to play a foundational role in pandemic preparedness, significantly reducing influenza-related morbidity and mortality. Ultimately, the successful development of a UIV will reshape the global influenza control landscape and enhance public health resilience.
